5337-09-7

Basic information

• Product Name: METHYL 2-BROMO-3-NITROBENZOATE
• Synonyms: METHYL 2-BROMO-3-NITROBENZOATE;2-BROMO-3-NITRO-BENZOIC ACID METHYL ESTER;2-bromo-3-nitro-benzoicacimethylester;3-Nitro-2-bromobenzoic acid methyl ester;Benzoic acid, 2-bromo-3-nitro-, methyl ester
• CAS NO: 5337-09-7
• Molecular Formula: C₈H₆BrNO₄
• Molecular Weight: 260.04
• Product Categories: pharmacetical
• Mol File: 5337-09-7.mol
• Article Data: 16

Chemical Properties

• Melting Point: 77 °C(Solv: methanol (67-56-1))
• Boiling Point: 300°Cat760mmHg
• Flash Point: 135.2°C
• Appearance: /
• Density: 1.673g/cm³
• Vapor Pressure: 0.00115mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform, DCM, Ethyl Acetate
• CAS DataBase Reference: METHYL 2-BROMO-3-NITROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-BROMO-3-NITROBENZOATE(5337-09-7)
• EPA Substance Registry System: METHYL 2-BROMO-3-NITROBENZOATE(5337-09-7)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 5337-09-7(Hazardous Substances Data)

Usage

Description

METHYL 2-BROMO-3-NITROBENZOATE, also known as 2-Bromo-3-nitrobenzoic Acid Methyl Ester, is a halogenated benzoic acid derivative that serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. Its chemical structure, which includes a bromine atom and a nitro group, provides it with unique properties that make it valuable in the development of medications.

Uses

Used in Pharmaceutical Industry:
METHYL 2-BROMO-3-NITROBENZOATE is used as an intermediate in the synthesis of anti-inflammatory drugs, specifically for the production of Balsalazide (B116300). This application is due to its ability to be chemically modified and incorporated into the structure of the final drug product, contributing to its therapeutic effects and potentially enhancing its anti-inflammatory properties.

InChI:InChI=1/C8H6BrNO4/c1-14-8(11)5-3-2-4-6(7(5)9)10(12)13/h2-4H,1H3

Upstream product

• 573-54-6 2-bromo-3-nitro-benzoic acid 
• 856789-07-6 bis-(2-methoxycarbonyl-6-nitro-phenyl)-mercury 
• 41085-43-2 2-bromo-3-nitrotoluene 
• 67-56-1 methanol 
• 53663-14-2 anhydro-2-hydroxymercuri-3-nitrobenzoic acid 
• 570-24-1 2-Methyl-6-nitroaniline 
• 74-88-4 methyl iodide 
• 57113-91-4 methyl 3-nitroanthranilate 

Downstream Products

• 857539-88-9 2-[1]naphthyl-3-nitro-benzoic acid methyl ester 
• 2436-96-6 1-nitro-2-(2-nitrophenyl)benzene 
• 2566-65-6 2',6-dinitro-2-carboxybiphenyl 
• 131514-77-7 methyl 3-nitro-2-<<2-<(phenylmethyl)amino>propyl>amino>benzoate 
• 77326-46-6 2-carbomethoxy-6-nitrobenzonitrile 
• 106896-48-4 methyl 2-bromo-3-aminobenzoate 
• 33358-47-3 2-Methoxycarbonyl-6-nitro-diphenylsulfid 
• 261351-28-4 2-(2-methoxy-3-phenyl-2,3-dihydro-benzofuran-6-ylamino)-3-nitro-benzoic acid methyl ester 
• 4518-10-9 Methyl 3-aminobenzoate 
• 109899-62-9 2-(4-methoxy-phenylamino)-3-nitro-benzoic acid methyl ester 
• 443303-80-8 2-(6-methoxycarbonyl-2-nitrophenyl)-2-cyclohexen-1-one 
• 328546-65-2 9-nitro-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one 

Relevant articles and documents

Organic electroluminescent device

The present invention relates to electronic devices, in particular organic electroluminescent devices, comprising compounds of the formula (1), to the corresponding compounds, and to a process for the preparation of these compounds.

EBNA1 INHIBITORS AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.

Monna, a potent and selective blocker for transmembrane protein with unknown function 16/anoctamin-1

Transmembrane protein with unknown function 16/anoctamin-1 (ANO1) is a protein widely expressed in mammalian tissues, and it has the properties of the classic calcium-activated chloride channel (CaCC). This protein has been implicated in numerous major physiological functions. However, the lack of effective and selective blockers has hindered a detailed study of the physiological functions of this channel. In this study, we have developed a potent and selective blocker for endogenous ANO1 in Xenopus laevis oocytes (xANO1) using a drug screening method we previously established (Oh et al., 2008). We have synthesized a number of anthranilic acid derivatives and have determined the correlation between biological activity and the nature and position of substituents in these derived compounds. A structure-activity relationship revealed novel chemical classes of xANO1 blockers. The derivatives contain a-NO2 group on position 5 of a naphthyl group-substituted anthranilic acid, and they fully blocked xANO1 chloride currents with an IC 5050 of 0.08 μM for xANO1. Selectivity tests revealed that other chloride channels such as bestrophin-1, chloride channel protein 2, and cystic fibrosis transmembrane conductance regulator were not appreciably blocked by 10～30 μM MONNA. The potent and selective blockers for ANO1 identified here should permit pharmacological dissection of ANO1/CaCC function and serve as potential candidates for drug therapy of related diseases such as hypertension, cystic fibrosis, bronchitis, asthma, and hyperalgesia.